Cargando…

Hierarchical cluster analysis of immunophenotype classify AML patients with NPM1 gene mutation into two groups with distinct prognosis

BACKGROUND: The prognostic implication of immunophenotyping in acute myeloid leukemia (AML) patients with NPM1 mutation remains unclear. METHODS: Ninety-four of 543 AML patients diagnosed with NPM1 mutation between 1987 and 2007 were studied. The expression of surface antigens on leukemic cells was...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chien-Yuan, Chou, Wen-Chien, Tsay, Woei, Tang, Jih-Luh, Yao, Ming, Huang, Sheng-Yi, Tien, Hwei-Fang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599624/ https://www.ncbi.nlm.nih.gov/pubmed/23496932 http://dx.doi.org/10.1186/1471-2407-13-107

Ejemplares similares

High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia
por: Chen, Chien-Yuan, et al.
Publicado: (2015)

Invasive fungal sinusitis in patients with hematological malignancy: 15 years experience in a single university hospital in Taiwan
por: Chen, Chien-Yuan, et al.
Publicado: (2011)

NPM1 and DNMT3A mutations are associated with distinct blast immunophenotype in acute myeloid leukemia
por: Kuželová, Kateřina, et al.
Publicado: (2022)

Intracranial hemorrhage in adult patients with hematological malignancies
por: Chen, Chien-Yuan, et al.
Publicado: (2012)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

The antagonistic duality of NPM1 mutations in AML
por: Khan, Irum, et al.
Publicado: (2022)

NPM 1 Mutations in AML—The Landscape in 2023
por: Sharma, Naman, et al.
Publicado: (2023)

Bone Marrow Clonogenic Myeloid Progenitors from NPM1-Mutated AML Patients Do Not Harbor the NPM1 Mutation: Implication for the Cell-Of-Origin of NPM1+ AML
por: Diaz de la Guardia, Rafael, et al.
Publicado: (2020)

Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies
por: Chen, Chien-Yuan, et al.
Publicado: (2011)

Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2014)

Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study
por: Huang, Shang-Yi, et al.
Publicado: (2015)

Clinical and Microbiological Characteristics of Perianal Infections in Adult Patients with Acute Leukemia
por: Chen, Chien-Yuan, et al.
Publicado: (2013)

Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia
por: Hou, Hsin-An, et al.
Publicado: (2016)

Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS)
por: Yao, Chi-Yuan, et al.
Publicado: (2016)

Targeted therapy in NPM1-mutated AML: Knowns and unknowns
por: Wang, Rong, et al.
Publicado: (2022)

Risk factors and clinical outcomes of acute myeloid leukaemia with central nervous system involvement in adults
por: Cheng, Chieh-Lung, et al.
Publicado: (2015)

Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML
por: Tsai, Xavier Cheng-Hong, et al.
Publicado: (2023)

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)
por: Fiskus, Warren, et al.
Publicado: (2022)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

CD123 Is Consistently Expressed on NPM1-Mutated AML Cells
por: Perriello, Vincenzo Maria, et al.
Publicado: (2021)

Hematopoietic differentiation at single-cell resolution in NPM1-mutated AML
por: Duchmann, Matthieu, et al.
Publicado: (2022)

Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan
por: Chen, Chien-Yuan, et al.
Publicado: (2018)

Soluble PD-L1: A biomarker to predict progression of autologous transplantation in patients with multiple myeloma
por: Huang, Shang-Yi, et al.
Publicado: (2016)

The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein
por: Pianigiani, Giulia, et al.
Publicado: (2022)

Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1
por: Mill, Christopher P., et al.
Publicado: (2023)

MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin
por: Lambert, Juliette, et al.
Publicado: (2014)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Spontaneous remission in three cases of AML M5 with NPM1 mutation
por: Camus, Vincent, et al.
Publicado: (2015)

Biological and therapeutic implications of a unique subtype of NPM1 mutated AML
por: Mer, Arvind Singh, et al.
Publicado: (2021)

Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field
por: Falini, Brunangelo, et al.
Publicado: (2021)

Comparison of Multiple Clinical Testing Modalities for Assessment of NPM1-Mutant AML
por: Lopez, Amanda, et al.
Publicado: (2021)

NPM1 Mutational Status Underlines Different Biological Features in Pediatric AML
por: Tregnago, Claudia, et al.
Publicado: (2021)

Current status and future perspectives in targeted therapy of NPM1-mutated AML
por: Ranieri, Roberta, et al.
Publicado: (2022)

Npm1 haploinsufficiency in collaboration with MEIS1 is sufficient to induce AML in mice
por: Muranyi, Andrew, et al.
Publicado: (2022)

Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML
por: Issa, Ghayas C., et al.
Publicado: (2022)

Long non-coding RNA HOXB-AS3 promotes myeloid cell proliferation and its higher expression is an adverse prognostic marker in patients with acute myeloid leukemia and myelodysplastic syndrome
por: Huang, Huai-Hsuan, et al.
Publicado: (2019)

ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden
por: Wang, Yu-Hung, et al.
Publicado: (2020)

Mutation of NPM1 and FLT3 Genes in Acute Myeloid Leukemia and Their Association with Clinical and Immunophenotypic Features
por: Chauhan, Pradeep Singh, et al.
Publicado: (2013)

A Knock-In Npm1 Mutation in Mice Results in Myeloproliferation and Implies a Perturbation in Hematopoietic Microenvironment
por: Chou, Shiu-Huey, et al.
Publicado: (2012)

Immunophenotypic characterisation of morphologically diagnosed cases of Acute Myeloid Leukaemia (AML)
por: Basharat, Maria, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gr5jikf3vtbf1j31hfihnsjbmk